| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Immutep Limited (NASDAQ: IMMP)
IMMP Technical Analysis
4
| As on 9th Jun 2023 IMMP STOCK Price closed @ 2.05 and we RECOMMEND Sell for LONG-TERM with Stoploss of 2.40 & Strong Sell for SHORT-TERM with Stoploss of 2.92 we also expect STOCK to react on Following IMPORTANT LEVELS. |
IMMPSTOCK Price
| Open | 2.05 | Change | Price | % |
| High | 2.10 | 1 Day | 0.00 | 0.00 |
| Low | 2.03 | 1 Week | 0.04 | 1.99 |
| Close | 2.05 | 1 Month | 0.41 | 25.00 |
| Volume | 200948 | 1 Year | -1.31 | -38.99 |
| 52 Week High 3.61 | 52 Week Low 1.54 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| IMMP Daily Charts |
IMMP Intraday Charts |
Whats New @ Bazaartrend |
IMMP Free Analysis |
|
|
IMMP Important Levels Intraday
| RESISTANCE | 2.18 |
| RESISTANCE | 2.14 |
| RESISTANCE | 2.11 |
| RESISTANCE | 2.09 |
| SUPPORT | 2.01 |
| SUPPORT | 1.99 |
| SUPPORT | 1.96 |
| SUPPORT | 1.92 |
IMMP Forecast May 2024
| 4th UP Forecast | 4.48 |
| 3rd UP Forecast | 3.7 |
| 2nd UP Forecast | 3.22 |
| 1st UP Forecast | 2.74 |
| 1st DOWN Forecast | 1.36 |
| 2nd DOWN Forecast | 0.88 |
| 3rd DOWN Forecast | 0.4 |
| 4th DOWN Forecast | -0.38 |
IMMP Weekly Forecast
| 4th UP Forecast | 2.61 |
| 3rd UP Forecast | 2.43 |
| 2nd UP Forecast | 2.32 |
| 1st UP Forecast | 2.21 |
| 1st DOWN Forecast | 1.89 |
| 2nd DOWN Forecast | 1.78 |
| 3rd DOWN Forecast | 1.67 |
| 4th DOWN Forecast | 1.49 |
IMMP Forecast2024
| 4th UP Forecast | 6.73 |
| 3rd UP Forecast | 5.23 |
| 2nd UP Forecast | 4.3 |
| 1st UP Forecast | 3.37 |
| 1st DOWN Forecast | 0.73 |
| 2nd DOWN Forecast | -0.2 |
| 3rd DOWN Forecast | -1.13 |
| 4th DOWN Forecast | -2.63 |
Immutep Limited ( NASDAQ USA Symbol : IMMP )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
IMMP Business Profile
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia. Address: 95 Pitt Street, Sydney, NSW, Australia, 2000
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service